These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37546399)

  • 21. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Mu W; Katsoulakis E; Whelan CJ; Gage KL; Schabath MB; Gillies RJ
    Br J Cancer; 2021 Jul; 125(2):229-239. PubMed ID: 33828255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.
    Yolchuyeva S; Giacomazzi E; Tonneau M; Lamaze F; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VSK
    JTO Clin Res Rep; 2023 Dec; 4(12):100602. PubMed ID: 38124790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer.
    Forouzannezhad P; Maes D; Hippe DS; Thammasorn P; Iranzad R; Han J; Duan C; Liu X; Wang S; Chaovalitwongse WA; Zeng J; Bowen SR
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
    Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
    J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy.
    Xie D; Xu F; Zhu W; Pu C; Huang S; Lou K; Wu Y; Huang D; He C; Hu H
    Front Oncol; 2022; 12():990608. PubMed ID: 36276082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
    Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Cousin F; Louis T; Dheur S; Aboubakar F; Ghaye B; Occhipinti M; Vos W; Bottari F; Paulus A; Sibille A; Vaillant F; Duysinx B; Guiot J; Hustinx R
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 33. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
    Wen Q; Yang Z; Dai H; Feng A; Li Q
    Front Oncol; 2021; 11():620246. PubMed ID: 34422625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
    Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
    EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying sarcopenia in advanced non-small cell lung cancer patients using skeletal muscle CT radiomics and machine learning.
    Dong X; Dan X; Yawen A; Haibo X; Huan L; Mengqi T; Linglong C; Zhao R
    Thorac Cancer; 2020 Sep; 11(9):2650-2659. PubMed ID: 32767522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.
    Gu Q; Feng Z; Liang Q; Li M; Deng J; Ma M; Wang W; Liu J; Liu P; Rong P
    Eur J Radiol; 2019 Sep; 118():32-37. PubMed ID: 31439255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
    Tankyevych O; Trousset F; Latappy C; Berraho M; Dutilh J; Tasu JP; Lamour C; Cheze Le Rest C
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishing a predictive model for tumor mutation burden status based on CT radiomics and clinical features of non-small cell lung cancer patients.
    Yang J; Shi W; Yang Z; Yu H; Wang M; Wei Y; Wen J; Zheng W; Zhang P; Zhao W; Chen L
    Transl Lung Cancer Res; 2023 Apr; 12(4):808-823. PubMed ID: 37197623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.
    He BX; Zhong YF; Zhu YB; Deng JJ; Fang MJ; She YL; Wang TT; Yang Y; Sun XW; Belluomini L; Watanabe S; Dong D; Tian J; Xie D
    Transl Lung Cancer Res; 2022 Apr; 11(4):670-685. PubMed ID: 35529789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.
    Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W
    Front Immunol; 2022; 13():828560. PubMed ID: 35464416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.